Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia

por Lo, Albert C., Evans, Cynthia Duggan, Mancini, Michele, Wang, Hong, Shcherbinin, Sergey, Lu, Ming, Natanegara, Fanni, Willis, Brian A.
Publicado 2021

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

por Gueorguieva, Ivelina, Willis, Brian A., Chua, Laiyi, Chow, Kay, Ernest, C. Steven, Wang, Jian, Shcherbinin, Sergey, Sims, John R., Chigutsa, Emmanuel
Publicado 2023

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

por Lowe, Stephen Loucian, Willis, Brian A., Hawdon, Anne, Natanegara, Fanni, Chua, Laiyi, Foster, Joanne, Shcherbinin, Sergey, Ardayfio, Paul, Sims, John R.
Publicado 2021

An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia

por Al‐Kofahi, Mahmoud, Ahmed, Mariam A., Jaber, Mutaz M., Tran, Thang N., Willis, Brian A., Zimmerman, Cheryl L., Gonzalez‐Bolanos, Maria T., Brundage, Richard C., Sarafoglou, Kyriakie
Publicado 2020

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial

por Willis, Brian A., Lo, Albert C., Dage, Jeffrey L., Shcherbinin, Sergey, Chinchen, Louise, Andersen, Scott W., LaBell, Elizabeth S., Perahia, David G.S., Hauck, Paula M., Lowe, Stephen L.
Publicado 2023

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

por Willis, Brian A., Sundell, Karen, Lachno, D. Richard, Ferguson-Sells, Lisa R., Case, Michael G., Holdridge, Karen, DeMattos, Ronald B., Raskin, Joel, Siemers, Eric R., Dean, Robert A.
Publicado 2018

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

por Shcherbinin, Sergey, Evans, Cynthia D., Lu, Ming, Andersen, Scott W., Pontecorvo, Michael J., Willis, Brian A., Gueorguieva, Ivelina, Hauck, Paula M., Brooks, Dawn A., Mintun, Mark A., Sims, John R.
Publicado 2022

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

por Wessels, Alette M., Tariot, Pierre N., Zimmer, Jennifer A., Selzler, Katherine J., Bragg, Sonja M., Andersen, Scott W., Landry, John, Krull, James H., Downing, AnnCatherine M., Willis, Brian A., Shcherbinin, Sergey, Mullen, Jamie, Barker, Peter, Schumi, Jennifer, Shering, Craig, Matthews, Brandy R., Stern, Robert A., Vellas, Bruno, Cohen, Sharon, MacSweeney, Emer, Boada, Mercè, Sims, John R.
Publicado 2020

Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species

por Willis, Brian A., Lowe, Stephen L., Monk, Scott A., Cocke, Patrick J., Aluise, Christopher D., Boggs, Leonard N., Borders, Anthony R., Brier, Richard A., Dean, Robert A., Green, Steven J., James, Douglas E., Jhee, Stanford S., Lin, Qun, Lo, Albert C., May, Patrick C., Watson, Brian M., Winneroski, Leonard L., Yang, Zhixiang, Zimmer, Jennifer A., McKinzie, David L., Mergott, Dustin J.
Publicado 2022